In Celexir’s muscle–recovery and fat-loss toolkit, AOD-9604 is positioned for patients who need adiposity reductionwithout stimulating the full growth-hormone axis. Clinically, it’s used as a precision adjunct inside structured body-recomposition programs—paired with nutrition periodization, resistance training, sleep, and glucose control—while Celexir’s ready-to-use pens, GMP documentation, and cold-chain handling keep protocols consistent from warehouse to administration.
Mechanistically, AOD-9604 is a GH fragment (176–191) engineered to stimulate lipolysis and inhibit lipogenesis—capturing GH’s fat-burning domain without meaningful effects on IGF-1 or glucose metabolism at studied doses. Preclinical work in obese rodents shows reduced weight gain and increased adipose tissue lipolytic activity; in obese mice, chronic dosing decreased body weight and fat mass with signals pointing to β3-adrenergic pathway involvement. Human safety summaries report no rise in IGF-1 and no adverse effect on oral glucose tolerance, supporting its “metabolic-selective” profile.
Evidence remains early and mixed: most efficacy data are animal or translational, with limited, small human studies to date. Accordingly, we frame AOD-9604 as an investigational adjunct—use objective tracking (waist/VAT, DXA when available, A1c, fasting insulin, CRP, fitness) and keep lifestyle pillars central so any signal translates into durable, health-span-relevant change.
Regulatory context & specs: AOD-9604 is not FDA-approved for weight loss; in Australia it’s a Schedule 4 prescription substance under TGA scheduling decisions. Celexir catalog specifications: 300–600 mcg/day per protocol, >98% purity (GMP-grade), 2–8 °C storage, prefilled injectable pen, with full CoA/MSDS to support compliance and repeatability. Use informed consent and clinic-level QC when deploying in research-oriented programs.